Balanced news tone
News Sentiment
HOWL sentiment intelligence
Werewolf Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
79/100 classification confidence.
directly relevant articles
high-authority source matches
+18.4% over one week, +5.8% over four weeks, trend inactive, and below fair value.
Price to earnings forward of Werewolf Therapeutics, Inc. – NASDAQ:HOWL
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Werewolf Therapeutics Insider Sold Shares Worth $280,210, According to a Recent SEC Filing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 May 2026 08:54
- Source
- MT Newswires
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 May 2026 07:00
- Source
- GlobeNewswire
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Werewolf Therapeutics explores sale and strategic alternatives
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Feb 2026 08:00
- Source
- Investing.com
Werewolf Therapeutics stock falls after announcing 64% workforce reduction
- Tone
- Negative 22/100
- Event
- Market update
- Published
- 13 Feb 2026 08:00
- Source
- Investing.com
Werewolf Therapeutics receives Nasdaq notice for minimum bid price deficiency
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Feb 2026 08:00
- Source
- Investing.com
Werewolf Therapeutics (HOWL) Eyes 2026 Catalysts Following FDA Guidance and Encouraging INDUKINE Results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jan 2026 08:00
- Source
- Market source
Werewolf Therapeutics Announces Pipeline and Business Updates
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Dec 2025 08:00
- Source
- GlobeNewswire
Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 23 Oct 2025 07:00
- Source
- Market source
Werewolf Therapeutics to Present Innovative Research at SITC 40th Annual Meeting | HOWL Stock News
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Oct 2025 07:00
- Source
- Quiver Quantitative